Pieris Pharmaceuticals (NASDAQ:PIRS) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Pieris Pharmaceuticals (NASDAQ:PIRS) from a sell rating to a hold rating in a report released on Monday morning.

Pieris Pharmaceuticals Stock Performance

Shares of NASDAQ:PIRS opened at $15.95 on Monday. Pieris Pharmaceuticals has a 12-month low of $6.20 and a 12-month high of $22.32. The company’s 50 day moving average price is $16.66 and its two-hundred day moving average price is $13.72.

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings results on Wednesday, August 14th. The biotechnology company reported ($2.76) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative return on equity of 75.34% and a negative net margin of 39.71%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. BML Capital Management LLC acquired a new position in shares of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 42,130 shares of the biotechnology company’s stock, valued at approximately $699,000. Pieris Pharmaceuticals makes up approximately 0.4% of BML Capital Management LLC’s holdings, making the stock its 21st largest position. BML Capital Management LLC owned approximately 3.19% of Pieris Pharmaceuticals at the end of the most recent quarter. 40.11% of the stock is currently owned by hedge funds and other institutional investors.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.